{
    "nct_id": "NCT00414622",
    "title": "A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2007-04-18",
    "description_brief": "A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease",
    "description_detailed": "A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "GTS-21 (DMXBA; 3-(2,4-dimethoxybenzylidene)anabaseine)"
    ],
    "placebo": [
        "Placebo"
    ],
    "explanation_target": [
        "Reason: The investigational drug GTS-21 is a synthetic small molecule that is a selective \u03b17 nicotinic acetylcholine receptor (\u03b17nAChR) agonist and was developed principally for cognitive enhancement in humans (clinical phase I/II work showed effects on attention, working memory and episodic memory). \ue200cite\ue202turn0search4\ue202turn1search3\ue201",
        "Act: Trial details \u2014 the study you provided is NCT00414622 (GTS21-201), a double-blind, randomized, placebo-controlled Phase 2 safety/tolerability study of multiple oral doses of GTS-21 administered for 28 days to participants with probable Alzheimer\u2019s disease. The drug is a small-molecule agonist (DMXBA/GTS-21) with preclinical reports also showing effects on A\u03b2 phagocytosis and \u03b3\u2011secretase activity, but its primary clinical development focus has been as a cognitive enhancer. \ue200cite\ue202turn1search0\ue202turn0search6\ue202turn0search5\ue201",
        "Reflect: Classification \u2014 I assign 'cognitive enhancer'. Rationale: although some preclinical work reports potential effects on amyloid handling, GTS-21 is a small\u2011molecule \u03b17nAChR agonist developed and tested in humans primarily to improve cognitive function; the cited clinical trial is a safety/tolerability study in AD patients rather than a targeted biologic (monoclonal antibody/vaccine) or a small\u2011molecule whose main intended mechanism is direct amyloid/tau enzymatic inhibition. If priority is given strictly to any disease\u2011pathology effect seen preclinically, one could argue for 'disease\u2011targeted small molecule', but the clinical development intent and mechanism support 'cognitive enhancer'. \ue200cite\ue202turn1search3\ue202turn0search6\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: GTS-21 (DMXBA) is a small-molecule selective agonist of the \u03b17 nicotinic acetylcholine receptor (\u03b17nAChR) and was developed principally as a cognitive enhancer acting on cholinergic neurotransmission. This mechanism is a neurotransmitter receptor\u2013directed intervention and therefore maps to CADRO category D. \ue200cite\ue202turn0search0\ue202turn1search6\ue201",
        "Act: The provided trial (NCT00414622 / GTS21-201) is a Phase 2, double\u2011blind, placebo\u2011controlled safety/tolerability study of oral GTS\u201121 in participants with probable Alzheimer\u2019s disease. While some preclinical studies report additional effects (reduced A\u03b2 burden via increased microglial A\u03b2 phagocytosis and suppression of \u03b3\u2011secretase activity), the primary clinical mechanism and development intent are agonism of the \u03b17 nicotinic receptor to improve cognition \u2014 a neurotransmitter receptor target. I therefore assign 'D) Neurotransmitter Receptors'. \ue200cite\ue202turn1search0\ue202turn0search1\ue201",
        "Reflect: Classification check \u2014 \u03b17nAChR is a ligand\u2011gated neurotransmitter receptor, so CADRO D is the best specific fit. Although preclinical literature shows possible downstream effects on amyloid handling and anti\u2011inflammatory actions, those are secondary/pleiotropic effects and do not change the primary target classification. If the trial drug were being developed primarily to modify amyloid or inflammation clinically, one could consider A) Amyloid beta or F) Inflammation or R) Multi-target, but here clinical intent supports D). \ue200cite\ue202turn0search1\ue202turn1search6\ue201",
        "Web search results (supporting sources):",
        "- PubMed review describing DMXBA (GTS\u201121) as an \u03b17 nicotinic agonist and cognitive effects. \ue200cite\ue202turn0search0\ue201",
        "- Preclinical study reporting that \u03b17\u2011selective agonist DMXBA promotes microglial A\u03b2 phagocytosis and suppresses neuronal \u03b3\u2011secretase activity (reducing A\u03b2) in an AD mouse model. \ue200cite\ue202turn0search1\ue201",
        "- ClinicalTrials record for NCT00414622 (GTS21\u2011201), the 28\u2011day randomized, double\u2011blind safety/tolerability study in probable AD. \ue200cite\ue202turn1search0\ue201",
        "- Phase I clinical study showing safety, pharmacokinetics and cognitive enhancement signals with multiple doses of GTS\u201121 in healthy volunteers. \ue200cite\ue202turn1search6\ue201",
        "- Review/chemistry summary of DMXBA (GTS\u201121) describing pharmacology and development as an \u03b17 agonist cognitive enhancer. \ue200cite\ue202turn0search5\ue201"
    ]
}